The Noramco Group LP Header@x2

HomeDCAT WeekThe Noramco Group LP Header@x2

Noramco CEO Lee Karras discusses $25 million Halo investment with PharmTech
Diversifying the Supply of Raw Materials
Noramco Announces Strategic Alignment with Purisys and Halo Pharma, Launching the Noramco Group as an Integrated North American-Based API and Drug Product Supply Chain Services Provider
Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit
Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide